trending Market Intelligence /marketintelligence/en/news-insights/trending/ceC2_UIMLuQ5ku3mHA4TgQ2 content esgSubNav
In This List

Thermo Fisher acquires GSK's Ireland-based manufacturing plant for €90M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Thermo Fisher acquires GSK's Ireland-based manufacturing plant for €90M

Thermo Fisher Scientific Inc. completed the €90 million acquisition of a Cork, Ireland-based manufacturing facility from GlaxoSmithKline PLC following regulatory approvals.

Waltham, Mass.-based Thermo Fisher said in an Oct. 1 press release that the site — which employs about 400 people — will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services segment.

The facility produces specialized active pharmaceutical ingredients for treating diseases that include childhood cancer, depression and Parkinson's. Under a multiyear supply agreement, Thermo Fisher will continue to produce pharmaceutical ingredients for U.K.-based GlaxoSmithKline and also expects to expand the use of the site to develop ingredients for other customers.